CoChat

β-Catenin and Smad3 regulate the activity and stability of myocardin-related transcription factor during epithelial–myofibroblast transition

Open access
Charbonney, Emmanuel, Speight, Pam, Masszi, András, Nakano, Hiroyasu, Kapus, András · 2011 · Molecular Biology of the Cell

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Injury to the adherens junctions (AJs) synergizes with transforming growth factor-β1 (TGFβ) to activate a myogenic program (α-smooth muscle actin [SMA] expression) in the epithelium during epithelial–myofibroblast transition (EMyT). Although this synergy plays a key role in organ fibrosis, the underlying mechanisms have not been fully defined. Because we recently showed that Smad3 inhibits myocardin-related transcription factor (MRTF), the driver of the SMA promoter and many other CC(A/T)-rich GG element (CArG) box–dependent cytoskeletal genes, we asked whether AJ components might affect SMA expression through interfering with Smad3. We demonstrate that E-cadherin down-regulation potentiates, whereas β-catenin knockdown inhibits, SMA expression. Contact injury and TGFβ enhance the binding of β-catenin to Smad3, and this interaction facilitates MRTF signaling by two novel mechanisms. First, it inhibits the Smad3/MRTF association and thereby allows the binding of MRTF to its myogenic partner, serum response factor (SRF). Accordingly, β-catenin down-regulation disrupts the SRF/MRTF complex. Second, β-catenin maintains the stability of MRTF by suppressing the Smad3-mediated recruitment of glycogen synthase kinase-3β to MRTF, an event that otherwise leads to MRTF ubiquitination and degradation and the consequent loss of SRF/MRTF–dependent proteins. Thus β-catenin controls MRTF-dependent transcription and emerges as a critical regulator of an array of cytoskeletal genes, the “CArGome.”

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1091/mbc.e11-04-0335

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1: E-Cadherin down-regulation facilitates TGFβ-induced SMA expression. (A) LLC-PK1 cells were transfected with NR or E-cadherin siRNA (E-cad si, 50 nM) and 24 h later, when confluent, treated with TGFβ (10 ng/ml) for 72 h. Cell lysates were prepared and probed by Western blotting (WB) for the indicated proteins. (B) Confluent monolayers transfected with NR or E-cadherin siRNA were treated with TGFβ for 72 h, immunostained for SMA, and visualized by fluorescence microscopy. (C) After transfection with NR or E-cadherin siRNA, subconfluent monolayers (70%) were treated with TGFβ for 72 h. Cell lysates were probed for the indicated proteins. (D) Densitometric quantification of GAPDH-normalized E-cadherin levels. (E) Densitometric quantification of the effect of E-cadherin down-regulation on SMA expression in subconfluent, TGFβ-treated monolayers, as shown in C.
FIGURE 1: E-Cadherin down-regulation facilitates TGFβ-induced SMA expression. (A) LLC-PK1 cells were transfected with NR or E-cadherin siRNA (E-cad si, 50 nM) and 24 h later, when confluent, treated with TGFβ (10 ng/ml) for 72 h. Cell lysates were prepared and probed by Western blotting (WB) for the indicated proteins. (B) Confluent monolayers transfected with NR or E-cadherin siRNA were treated with TGFβ for 72 h, immunostained for SMA, and visualized by fluorescence microscopy. (C) After transfection with NR or E-cadherin siRNA, subconfluent monolayers (70%) were treated with TGFβ for 72 h. Cell lysates were probed for the indicated proteins. (D) Densitometric quantification of GAPDH-normalized E-cadherin levels. (E) Densitometric quantification of the effect of E-cadherin down-regulation on SMA expression in subconfluent, TGFβ-treated monolayers, as shown in C.CC BY-NC-SA · PubMed Central
FIGURE 2: β-Catenin is a crucial permissive regulator of SMA expression. (A) Confluent LLC-PK1 cells transfected with NR or β-catenin siRNA (β-cat si, 100 nM) were exposed to combined treatment (TGFβ + LCM) for 48 h. Cell lysates were probed by WB for the indicated proteins. (B) The effect of the β-catenin down-regulation on the two-hit stimulation–triggered SMA expression. (C) Quantification of SMA mRNA by quantitative PCR in NR or β-catenin siRNA-transfected cells. siRNAs were added 24 h prior to stimulation with the two-hit regimen for 48 h. (D) One day after transfection with NR or β-catenin siRNA (100 nM), cells were cotransfected with SMA-Luc and pRL-TK for 24 h and then exposed to LCM plus TGFβ for an additional 24 h, followed by luminometric determination of SMA promoter activity. (E) The effect of β-catenin silencing on SMA expression in E-cadherin–depleted and TGFβ-stimulated monolayers. Cells were transfected with various siRNAs alone or in combination (NR, E-cad, β-cat, or E-cad + β-cat, labeled as E/β), treated with TGFβ for 72 h, and probed by Western blotting for the indicated proteins. (F) The impact of E-cadherin down-regulation on β-catenin localization. β-Catenin was detected in nuclear extracts prepared from cells transfected with NR or E-cadherin siRNA (24 h). (G) Densitometric quantification of nuclear β-catenin normalized to total. (H) The effect of LCM plus TGFβ treatment on the cytosolic β-catenin signal. Confluent monolayers were exposed to vehicle (control) or combined stimulation for 6 h, after which cells were fixed and stained for β-catenin and DAPI (left) and the normalized cytosolic β-catenin signal was quantified (right) as described in Materials and Methods. (I) β-Catenin overexpression is not sufficient to drive the SMA promoter. SMA promoter activity was measured in cells transfected with empty vector or β-catenin (3 μg) together with the SMA-Luc/pRL-TK system (24 h) and then exposed to vehicle or the combined treatment for an additional day.
FIGURE 2: β-Catenin is a crucial permissive regulator of SMA expression. (A) Confluent LLC-PK1 cells transfected with NR or β-catenin siRNA (β-cat si, 100 nM) were exposed to combined treatment (TGFβ + LCM) for 48 h. Cell lysates were probed by WB for the indicated proteins. (B) The effect of the β-catenin down-regulation on the two-hit stimulation–triggered SMA expression. (C) Quantification of SMA mRNA by quantitative PCR in NR or β-catenin siRNA-transfected cells. siRNAs were added 24 h prior to stimulation with the two-hit regimen for 48 h. (D) One day after transfection with NR or β-catenin siRNA (100 nM), cells were cotransfected with SMA-Luc and pRL-TK for 24 h and then exposed to LCM plus TGFβ for an additional 24 h, followed by luminometric determination of SMA promoter activity. (E) The effect of β-catenin silencing on SMA expression in E-cadherin–depleted and TGFβ-stimulated monolayers. Cells were transfected with various siRNAs alone or in combination (NR, E-cad, β-cat, or E-cad + β-cat, labeled as E/β), treated with TGFβ for 72 h, and probed by Western blotting for the indicated proteins. (F) The impact of E-cadherin down-regulation on β-catenin localization. β-Catenin was detected in nuclear extracts prepared from cells transfected with NR or E-cadherin siRNA (24 h). (G) Densitometric quantification of nuclear β-catenin normalized to total. (H) The effect of LCM plus TGFβ treatment on the cytosolic β-catenin signal. Confluent monolayers were exposed to vehicle (control) or combined stimulation for 6 h, after which cells were fixed and stained for β-catenin and DAPI (left) and the normalized cytosolic β-catenin signal was quantified (right) as described in Materials and Methods. (I) β-Catenin overexpression is not sufficient to drive the SMA promoter. SMA promoter activity was measured in cells transfected with empty vector or β-catenin (3 μg) together with the SMA-Luc/pRL-TK system (24 h) and then exposed to vehicle or the combined treatment for an additional day.CC BY-NC-SA · PubMed Central
FIGURE 3: TGFβ and LCM facilitate the association of Smad3 and β-catenin. (A) Confluent cells were treated for 1 h as indicated, followed by immunoprecipitation of Smad3. The precipitates and cell lysate inputs were subjected to WB and probed for the indicated proteins. (B) Densitometric quantification of the coprecipitated β-catenin under various conditions. (C) E-cadherin silencing (50 nM siRNA for 24 h) is sufficient to facilitate the association of β-catenin with Smad3.
FIGURE 3: TGFβ and LCM facilitate the association of Smad3 and β-catenin. (A) Confluent cells were treated for 1 h as indicated, followed by immunoprecipitation of Smad3. The precipitates and cell lysate inputs were subjected to WB and probed for the indicated proteins. (B) Densitometric quantification of the coprecipitated β-catenin under various conditions. (C) E-cadherin silencing (50 nM siRNA for 24 h) is sufficient to facilitate the association of β-catenin with Smad3.CC BY-NC-SA · PubMed Central
FIGURE 4: β-Catenin counteracts the inhibitory action of Smad3 on the SMA promoter through SBE-independent, CArG-dependent mechanism. The inhibitory effect of Smad3 on the SMA promoter was titrated by cotransfecting various amounts of Smad3 expression plasmid with MRTF (0.5 μg) and the SMA-Luc/pRL-TK reporter. SMA promoter activity obtained with MRTF alone was taken as 100%. (B) Cells were cotransfected with SMA-Luc/pRL-TK, MRTF (0.5 μg), Smad3 (1 μg), and increasing amounts of β-catenin. The Smad3-induced inhibition of the SMA promoter was reversed by β-catenin in a dose-dependent manner. (C) Combinatorial expression of the indicated transcription factors along with WT and mutant SMA promoter constructs (Triple or Short mutant; see Materials and Methods). Activation of the SMA promoter by MRTF (M, 0.5 μg) was inhibited by Smad3 (S, 1 μg). This inhibitory effect was completely reversed by β-catenin (3 μg).
FIGURE 4: β-Catenin counteracts the inhibitory action of Smad3 on the SMA promoter through SBE-independent, CArG-dependent mechanism. The inhibitory effect of Smad3 on the SMA promoter was titrated by cotransfecting various amounts of Smad3 expression plasmid with MRTF (0.5 μg) and the SMA-Luc/pRL-TK reporter. SMA promoter activity obtained with MRTF alone was taken as 100%. (B) Cells were cotransfected with SMA-Luc/pRL-TK, MRTF (0.5 μg), Smad3 (1 μg), and increasing amounts of β-catenin. The Smad3-induced inhibition of the SMA promoter was reversed by β-catenin in a dose-dependent manner. (C) Combinatorial expression of the indicated transcription factors along with WT and mutant SMA promoter constructs (Triple or Short mutant; see Materials and Methods). Activation of the SMA promoter by MRTF (M, 0.5 μg) was inhibited by Smad3 (S, 1 μg). This inhibitory effect was completely reversed by β-catenin (3 μg).CC BY-NC-SA · PubMed Central
FIGURE 5: β-Catenin protects the SRF/MRTF myogenic complex. (A) Cells were cotransfected with vectors encoding the indicated tagged proteins for 48 h, followed by lysis and immunoprecipitation of Myc-MRTF using an anti-Myc antibody. Under basal conditions MRTF pulled down SRF (anti-HA, lane 4). Smad3 coexpression reduced the SRF/MRTF interaction, whereas β-catenin coexpression (lanes 2 and 3) restored their association. (B) Confluent monolayers transfected with NR or β-catenin siRNA (48 h) were treated for 30 min with the combined treatment (TGFβ + LCM), followed by the immunoprecipitation of endogenous MRTF. (C, D) To induce nuclear MRTF translocation, monolayers transfected as in B were treated with LCM for 30 min. Cells were then costained for MRTF and β-catenin (C) or nuclear extracts were prepared and probed for MRTF (D).
FIGURE 5: β-Catenin protects the SRF/MRTF myogenic complex. (A) Cells were cotransfected with vectors encoding the indicated tagged proteins for 48 h, followed by lysis and immunoprecipitation of Myc-MRTF using an anti-Myc antibody. Under basal conditions MRTF pulled down SRF (anti-HA, lane 4). Smad3 coexpression reduced the SRF/MRTF interaction, whereas β-catenin coexpression (lanes 2 and 3) restored their association. (B) Confluent monolayers transfected with NR or β-catenin siRNA (48 h) were treated for 30 min with the combined treatment (TGFβ + LCM), followed by the immunoprecipitation of endogenous MRTF. (C, D) To induce nuclear MRTF translocation, monolayers transfected as in B were treated with LCM for 30 min. Cells were then costained for MRTF and β-catenin (C) or nuclear extracts were prepared and probed for MRTF (D).CC BY-NC-SA · PubMed Central
FIGURE 6: β-Catenin inhibits the association of Smad3 with MRTF. (A) Cells were cotransfected with the indicated vectors for 24 h, followed by immunoprecipitation of HA-MRTF. The precipitates and the input were probed for the indicated proteins. (B) Cells were transfected with NR or β-catenin siRNA for 24 h and then cotransfected with the indicated vectors for another 24 h. Similar coprecipitation experiments were performed as in A. (C) WT or ΔB1p HA-MRTF (which has impaired Smad3-binding capacity) were expressed and immunoprecipitated by an anti-HA antibody. Coprecipitating proteins were detected by WB. (D) Endogenous MRTF was precipitated with the BSAC antibody from cells that had been pretreated with NR or Smad3 siRNA (50 nM) for 48 h. Coprecipitating proteins were detected by WB. (E) Confluent cells were exposed to TGFβ plus LCM for the indicated times, followed by MRTF immunoprecipitation. The precipitates were probed for β-catenin.
FIGURE 6: β-Catenin inhibits the association of Smad3 with MRTF. (A) Cells were cotransfected with the indicated vectors for 24 h, followed by immunoprecipitation of HA-MRTF. The precipitates and the input were probed for the indicated proteins. (B) Cells were transfected with NR or β-catenin siRNA for 24 h and then cotransfected with the indicated vectors for another 24 h. Similar coprecipitation experiments were performed as in A. (C) WT or ΔB1p HA-MRTF (which has impaired Smad3-binding capacity) were expressed and immunoprecipitated by an anti-HA antibody. Coprecipitating proteins were detected by WB. (D) Endogenous MRTF was precipitated with the BSAC antibody from cells that had been pretreated with NR or Smad3 siRNA (50 nM) for 48 h. Coprecipitating proteins were detected by WB. (E) Confluent cells were exposed to TGFβ plus LCM for the indicated times, followed by MRTF immunoprecipitation. The precipitates were probed for β-catenin.CC BY-NC-SA · PubMed Central
FIGURE 7: β-Catenin regulates MRTF stability and ubiquitination in a GSK-3β–dependent manner. (A) Confluent monolayers transfected with NR or β-catenin siRNA (48 h) were exposed for the indicated times to the combined treatment (TGFβ + LCM) and then lysed and probed for the indicated proteins, revealing a marked reduction in the MRTF (BSAC) immunoreactive band in the β-catenin–depleted and stimulated samples. In many experiments this decrease was detectable at 60 min but became significant (and was present in all experiments) after 90 min. (B) Cells were treated as in A following transfection with HA-MRTF. Lysates were probed with an anti-HA antibody. Graphs for A and B, densitometric quantification of the MRTF signal. Inset, quantification of MRTF by another polyclonal anti–MRTF-B antibody (C-19). (C) Confluent monolayers, transfected with NR or β-catenin siRNA (48 h), were pretreated with vehicle, LiCl (15 mM), or a GSK inhibitor (30 μM, GSKi) for 30 min and then left untreated (−) or exposed to the combined treatment for 120 min. Note that inhibition of GSK-3β prevents the loss of the MRTF signal observed in β-catenin–depleted, stimulated cells. (D) Monolayers cotransfected as in B were pretreated with LiCl (15 mM, 30 min) and then exposed for 60 min to the combined treatment. Subsequently anti-HA (MRTF) immunoprecipitates were probed with a polyubiquitin antibody.
FIGURE 7: β-Catenin regulates MRTF stability and ubiquitination in a GSK-3β–dependent manner. (A) Confluent monolayers transfected with NR or β-catenin siRNA (48 h) were exposed for the indicated times to the combined treatment (TGFβ + LCM) and then lysed and probed for the indicated proteins, revealing a marked reduction in the MRTF (BSAC) immunoreactive band in the β-catenin–depleted and stimulated samples. In many experiments this decrease was detectable at 60 min but became significant (and was present in all experiments) after 90 min. (B) Cells were treated as in A following transfection with HA-MRTF. Lysates were probed with an anti-HA antibody. Graphs for A and B, densitometric quantification of the MRTF signal. Inset, quantification of MRTF by another polyclonal anti–MRTF-B antibody (C-19). (C) Confluent monolayers, transfected with NR or β-catenin siRNA (48 h), were pretreated with vehicle, LiCl (15 mM), or a GSK inhibitor (30 μM, GSKi) for 30 min and then left untreated (−) or exposed to the combined treatment for 120 min. Note that inhibition of GSK-3β prevents the loss of the MRTF signal observed in β-catenin–depleted, stimulated cells. (D) Monolayers cotransfected as in B were pretreated with LiCl (15 mM, 30 min) and then exposed for 60 min to the combined treatment. Subsequently anti-HA (MRTF) immunoprecipitates were probed with a polyubiquitin antibody.CC BY-NC-SA · PubMed Central
FIGURE 8: Smad3 recruits GSK-3β to MRTF and is necessary for MRTF degradation. (A) Monolayers transfected with NR, β-catenin, or Smad3 siRNA (48 h) were exposed for various times to the combined treatment. Cells were then lysed, MRTF was immunoprecipitated, and the precipitates and inputs were probed for GSK-3β and other indicated proteins. (B) Endogenous MRTF was immunoprecipitated from cells that had been transfected with various siRNAs (NR, β-catenin, Smad3, or β-catenin + Smad3) and then treated with vehicle (−) or TGFβ plus LCM for 60 min. Note that the MRTF/GSK-3β association, seen in β-catenin–depleted and stimulated cells, is abolished by the concomitant down-regulation of Smad3. (C) Smad3-binding capacity of MRTF is critical for the recruitment of GSK-3β to MRTF. Cells transfected with NR or β-catenin siRNA and WT or ΔB1p (Smad3-binding–deficient mutant) HA-MRTF were exposed for 60 min to the combined treatment. Anti-HA immunoprecipitates and inputs were probed for the indicated proteins.
FIGURE 8: Smad3 recruits GSK-3β to MRTF and is necessary for MRTF degradation. (A) Monolayers transfected with NR, β-catenin, or Smad3 siRNA (48 h) were exposed for various times to the combined treatment. Cells were then lysed, MRTF was immunoprecipitated, and the precipitates and inputs were probed for GSK-3β and other indicated proteins. (B) Endogenous MRTF was immunoprecipitated from cells that had been transfected with various siRNAs (NR, β-catenin, Smad3, or β-catenin + Smad3) and then treated with vehicle (−) or TGFβ plus LCM for 60 min. Note that the MRTF/GSK-3β association, seen in β-catenin–depleted and stimulated cells, is abolished by the concomitant down-regulation of Smad3. (C) Smad3-binding capacity of MRTF is critical for the recruitment of GSK-3β to MRTF. Cells transfected with NR or β-catenin siRNA and WT or ΔB1p (Smad3-binding–deficient mutant) HA-MRTF were exposed for 60 min to the combined treatment. Anti-HA immunoprecipitates and inputs were probed for the indicated proteins.CC BY-NC-SA · PubMed Central
FIGURE 9: β-Catenin maintains expression of CArG-dependent proteins. Cells transfected with NR or β-catenin siRNA (100 nM, 24 h) were left untreated or exposed for 48 h to TGFβ plus LCM. Cell lysates were prepared and probed for a panel of CArG-dependent proteins. (B) Densitometric quantification of the implicated CArG proteins. (C) Proposed model of the β-catenin– and Smad3-dependent regulation of MRTF. At high β-catenin levels, Smad3 associates with β-catenin, which prevents the Smad3-induced disruption of the myogenic complex (MRTF/SRF) and maintains MRTF activity. At lower β-catenin levels, Smad3 associates with MRTF and inhibits the formation of the myogenic complex. Moreover, Smad3 recruits GSK-3β, which in turn promotes MRTF degradation.
FIGURE 9: β-Catenin maintains expression of CArG-dependent proteins. Cells transfected with NR or β-catenin siRNA (100 nM, 24 h) were left untreated or exposed for 48 h to TGFβ plus LCM. Cell lysates were prepared and probed for a panel of CArG-dependent proteins. (B) Densitometric quantification of the implicated CArG proteins. (C) Proposed model of the β-catenin– and Smad3-dependent regulation of MRTF. At high β-catenin levels, Smad3 associates with β-catenin, which prevents the Smad3-induced disruption of the myogenic complex (MRTF/SRF) and maintains MRTF activity. At lower β-catenin levels, Smad3 associates with MRTF and inhibits the formation of the myogenic complex. Moreover, Smad3 recruits GSK-3β, which in turn promotes MRTF degradation.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 65 references

Research works printed but not linked: 1

  1. Kim KK, 2009, J Clin Invest, 119, 213

Cited by

See all 84

Metadata

Authors
Charbonney, E., Speight, P., Masszi, A., Nakano, H., & Kapus, A.
Affiliations
  • St. Michael's Hospital (CA)
  • Juntendo University (JP)
  • Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Department of Surgery, University of Toronto, Toronto, ON M5B 1W8, Canada
Venue
Molecular Biology of the Cell
Published
2011-12
Volume
22
Issue
23
Pages
4472-4485
ISSN
  • 1059-1524 (ISSN-L)
  • 1939-4586
OpenAlex
W2129055432
Cited by
84
References
65
Citations by year
2026: 2 · 2024: 2 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 2 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 9 · 2015: 9 · 2014: 10 · 2013: 10 · 2012: 6
FWCI
3.37
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Molecular Biology of the Cell (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
  • Kidney Foundation of Canada
  • Canadian Institutes of Health Research (MOP- 106625, 86535_1, TGF-53877)
  • Japan Society for the Promotion of Science (23659404)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
Keywords
β-catenin, Smad3, MRTF, adherens junctions, E-cadherin, TGF-β1, serum response factor, glycogen synthase kinase-3β, protein stability, ubiquitination, alpha-smooth muscle actin, organ fibrosis, CArG box
MeSH terms
Glycogen Synthase Kinase 3 beta, Actins, Animals, Cells, Cultured, Epithelial Cells, Gene Expression Regulation, Promoter Regions, Genetic, Swine, Transcription Factors, Cadherins, Transforming Growth Factor beta, Adherens Junctions, Serum Response Factor, Glycogen Synthase Kinase 3, beta Catenin, Rats, Smad3 Protein, Protein Stability, Myofibroblasts, Epithelial-Mesenchymal Transition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: β-Catenin and Smad3 regulate the activity and stability of myocardin-related transcription factor during epithelial–myofibroblast transition. https://app.cochat.ai/papers/10.1091/mbc.e11-04-0335
The paper
Charbonney, E., Speight, P., Masszi, A., Nakano, H., & Kapus, A. (2011). β-Catenin and Smad3 regulate the activity and stability of myocardin-related transcription factor during epithelial–myofibroblast transition. Molecular Biology of the Cell. https://doi.org/10.1091/mbc.e11-04-0335

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.